Dror Bashan - 03 Sep 2026 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: PLX
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Sep 2026, 06:00:19 UTC
Prior SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Magnas, Attorney-in-Fact

Key filing fact

Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 04 Sep 2026.

Key facts

This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Sep 2026, 06:00.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001781450 Primary reporting owner

Bashan Dror

Relationship: PRESIDENT AND CEO, Director
Address: C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Signature date: 04 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +320,000
Change %
Price: $0.000000^*
Shares after: 320,000
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 320,000
Exercise price: $2.59
Footnotes: F1, F2

PLX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +160,000
Change %
Price: $0.000000^*
Shares after: 160,000
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 160,000
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.

Footnote F2

Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

Footnote F3

Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

Footnote F4

The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.